WINREVAIR™ (sotatercept-csrk) Reduced the Risk of Clinical Worsening Events by 76% Compared to Placebo in Patients Recently Diagnosed With PAH on Backgroun…

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive results from the Phase 3 ...